Striate US Market Entry Update
Filed with ASX · · 2 pages · English
• US Key opinion leader sales growth milestone of 1,500 Striate+™ units achieved • Approvals received to upgrade existing facility and scale up Striate+™ manufacturing capacity to >100,000 units per year • Commissioning of upgraded facility expected Q4 CY2022 • Distributor discussions progressed and the Company is in advanced discussions to engage its first US distributor andestablish Striate+™ as
Earlier from Orthocell
- Application for quotation of securities - OCC
- Successful SmrtGraft Shoulder Study Published
- OrthoATI Tendon Clinical Study Success
- Ortho-ATI Shoulder Tendon Study Database Lock
- Positive Data for CelGro Collagen Rope in ACL Reconstruction
Later from Orthocell
- Regulatory Approval for Remplir Nerve Repair Device
- Notification regarding unquoted securities - OCC
- Orthocell Receives A$2.1m R&D Tax Incentive Refund
- Final Data Readout for Orthocells Nerve Reconstruction Study
- OCC Signs Striate Global License And Manufacturing Agreement
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell